Neurogen, Pfizer start AD Phase II

NRGN partner PFE began double-blind U.S. Phase II testing of NRGN's NGD 97-1 GABA modulator in 200 patients with Alzheimer's disease (AD). Patients will receive one of three NGD 97-1 doses, placebo or...